Skip to main content

Table 5 Pattern of compliance to chemotherapy by age and radiotherapy

From: Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

Variable Age Radiotherapy
  >60 and < 65 (n = 100) ≥ 65 (n = 80) P§ No* (n = 114) Yes (n = 66) P§
N. of cycles administered, no. (%)    0.42    0.01
6 cycles 81 (81) 61 (76)   84 (74) 58 (88)  
5 cycles 5 (5) 4 (5)   4 (3) 5 (8)  
4 cycles 4 (4) 4 (5)   6 (5) 2 (3)  
3 cycles 5 (5) 6 (8)   10 (9) 1 (1)  
2 cycles 4 (4) 4 (5)   8 (7) 0  
1 cycle 1 (1) 1 (1)   2 (2) 0  
N. of day 8 omitted, no. (%)    0.37    0.86
0 69 (69) 51 (64)   77 (68) 43 (65)  
1 23 (23) 18 (22)   24 (21) 17 (26)  
2 5 (5) 8 (10)   9 (8) 4 (6)  
3 3 (3) 3 (4)   4 (3) 2 (3)  
Rate of cycles at reduced dose, no. (%)    0.54    0.83
≤ 25% 86 (86) 66 (82)   97 (85) 55 (83)  
>25% 14 (14) 14 (18)   17 (15) 11 (17)  
Actual/planned duration, no. (%)    0.59    0.05
≤ 1.25 99 (99) 78 (98)   114 (100) 63 (95)  
>1.25 1 (1) 2 (2)   0 3 (5)  
G-CSF utilization, no. (%)    0.12   <.0001  
No 91 (91) 66 (82)   109 (96) 48 (73)  
Yes 9 (9) 14 (18)   5 (4) 18 (27)  
Treatment discontinuation, no. (%)    0.52    0.10
protocol completion 81 (81) 61 (76)   84 (74) 58 (88)  
patient's refusal 6 (6) 9 (11)   12 (11) 3 (4)  
treatment toxicity 11 (11) 7 (9)   13 (11) 5 (8)  
other 2 (2) 3 (4)   5 (4) 0  
Low compliance, no. (%)    0.02    0.88
No 61 (61) 34 (42)   61 (54) 34 (52)  
yes 39 (39) 46 (58)   53 (46) 32 (48)  
  1. * including 21 patients who received radiotherapy after the end of chemotherapy
  2. § Fisher exact test or Wilcoxon-Mann Whitney test for naturally ordered variables)
  3. † at least one of the following features: less than 6 cycles administered, withdrawal of more than one day-8 treatment, dose reduction in more than 25% of cycles, relative duration higher than 1.25, use of G-CSF treatment, treatment interruption because of patient's refusal or toxicity